Regulators like to see two P3 studies, but there are exceptions of course and they are not the rule - simple as that!
I don't by default assume exceptions because I've invested in some biotech, I tend to view it from the rules perspective and be delighted when exceptions that I might think possible do occur.
Market Data 
Markets 
AI
